Business Wire

Bermuda Represented at International Private Client Forum in Lake Como, Italy

22.11.2022 16:37:00 EET | Business Wire | Press release

Share

From November 17-19, a delegation from Bermuda travelled to Lake Como, Italy to promote Bermuda as a premier domicile for high-net-worth services to private client lawyers from all over the world

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005517/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bermuda representatives (from left) Alec Anderson, Quadrant Advisors; Lorinda Gazzard, Butterfield; Keith Robinson, Carey Olsen; Randall Krebs, Harbour International Trust Company; Scott Pearman, Conyers; Craig W. MacIntyre, Conyers; David Hart, BDA; Andrea Jackson, BDA; Michael Neff, Butterfield; Kevin Dallas, Butterfield; Nir Sadeh, Butterfield; Jeffrey P. Elkinson, Conyers; Gina Pereira, Meritus Trust. (Photo: Business Wire)

Representing the BDA was CEO David Hart and independent board member, Andrea Jackson, while senior representatives from Butterfield, Carey Olsen, Conyers, Harbour International, Meritus Trust, and Quadrant Advisors were also in attendance.

David Hart said, “The BDA’s main purpose here at the International Private Client Forum, which is held in association with Butterfield, is to share the message of Bermuda's safety and stability as a blue-chip jurisdiction for attracting and welcoming foreign direct investment. There is a larger Bermuda delegation here beyond the BDA, including leading professionals in our legal, banking and trust communities, all of whom have substantial experience in advising high net worth individuals and families and are at the forefront of the private wealth industry.”

Michael Neff, Butterfield’s Managing Director of Bermuda and International Wealth, welcomed delegates to the three-day forum of panel discussions, roundtables and workshops. Carey Olsen Bermuda partner and head of the Bermuda disputes team, Keith Robinson, spoke on a panel session entitled 'Drafting Carefully: Planning Lessons Learned from Recent Cases' and Conyers director Scott Pearman joined a roundtable discussion entitled ‘Criminal Enforcement: Our Shifting Role’.

Bermuda’s attendance at what is referred to as the world’s preeminent gathering of private client lawyers builds on three major in-person high-net-worth services events that returned to Bermuda this summer, the first since 2019.

Along with Butterfield, the BDA co-sponsored a ‘Private Client Exchange Bermuda 2022’ event in June 28-29. This sold-out event brought about 50 of the world’s top lawyers to the St Regis Bermuda Resort.

As part of our commitment to Bermuda’s high net worth services industry, the BDA also sponsored two other in-person international trust and private investors events in June and July. These events not only brought global trust and legal leaders to the Island to discuss important hot topics and best practices but the immediate economic impact of the first two, including lodging, transportation, food and beverage, retail and recreation, was estimated at over half million dollars, and supported around 240 jobs.

If you would like to learn more about Bermuda’s high-net-worth services sector, contact Korrin Lightbourne, Senior Business Development Coordinator at info@bda.bm or +1 441 292 0632.

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stuart Roberts, Director of Communications & PR
stuart@bda.bm | +1 441 292 7774

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye